Trustmark Corporation filed a Form 8-K on September 10, 2026, disclosing that its subsidiary Trustmark Bank completed a sale-leaseback transaction on September 3, 2026, selling 34 branch properties to affiliates of Blue Owl Real Estate Capital LLC for $91.7 million and simultaneously leasing them …
Corteva, Inc. and subsidiary EIDP, Inc. filed an 8-K on September 10, 2026, disclosing that on September 9, 2026, the company, along with The Chemours Company and DuPont de Nemours, Inc., reached a settlement with the State of North Carolina and multiple state subdivisions …
Qnity Electronics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on September 10, 2026, disclosing an indemnification liability related to a PFAS settlement involving DuPont de Nemours, The Chemours Company, and Corteva Inc.
Equity LifeStyle Properties, Inc. filed a Form 8-K current report on September 10, 2026, disclosing under Item 7.01 (Regulation FD) that a September 2026 investor presentation had been made available to investors as of that date.
Huntington Bancshares Incorporated filed a Form 8-K on September 10, 2026, disclosing the appointment of Brantley J. Standridge as President of the company and its subsidiary The Huntington National Bank, effective September 8, 2026.
Candel Therapeutics, Inc. filed a Form 8-K on September 10, 2026, disclosing the appointment of Martine Zimmermann, Pharm.D., to its Board of Directors, effective September 8, 2026, and detailing her compensation arrangements.
Ramaco Resources, Inc. filed a Form 8-K on September 10, 2026, disclosing that former U.S. Senator Joseph Manchin III resigned from the company's Board of Directors, effective September 4, 2026.
Arrow Financial Corporation filed a current report on September 10, 2026, announcing that its subsidiary Upstate Agency, LLC has entered into a definitive agreement to acquire Skene Valley Agency, Inc., an independent insurance agency located in Washington County, New York.
BKV Corporation filed a Form 8-K on September 9, 2026, disclosing the proposed and subsequently priced upsized offering of $500 million in aggregate principal amount of 1.625% convertible senior notes due 2031 under Rule 144A.
Disc Medicine, Inc. filed an 8-K with the U.S. Securities and Exchange Commission on September 10, 2026, disclosing initial results from the Phase 2 RESTORE-PV clinical trial of DISC-3405 in patients with polycythemia vera.